EP1974722A3 - Formules de dosage de tacrolimus modifiées - Google Patents

Formules de dosage de tacrolimus modifiées Download PDF

Info

Publication number
EP1974722A3
EP1974722A3 EP08006027A EP08006027A EP1974722A3 EP 1974722 A3 EP1974722 A3 EP 1974722A3 EP 08006027 A EP08006027 A EP 08006027A EP 08006027 A EP08006027 A EP 08006027A EP 1974722 A3 EP1974722 A3 EP 1974722A3
Authority
EP
European Patent Office
Prior art keywords
tacrolimus
amount
hours
released
dosage forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08006027A
Other languages
German (de)
English (en)
Other versions
EP1974722A2 (fr
Inventor
Rajesh Jain
Amarjit Singh
Sarabjit Singh
Shivanand Puthli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Biotec Ltd
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39642954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1974722(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of EP1974722A2 publication Critical patent/EP1974722A2/fr
Publication of EP1974722A3 publication Critical patent/EP1974722A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP08006027A 2007-03-29 2008-03-28 Formules de dosage de tacrolimus modifiées Withdrawn EP1974722A3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN583MU2007 2007-03-29

Publications (2)

Publication Number Publication Date
EP1974722A2 EP1974722A2 (fr) 2008-10-01
EP1974722A3 true EP1974722A3 (fr) 2009-03-04

Family

ID=39642954

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08006027A Withdrawn EP1974722A3 (fr) 2007-03-29 2008-03-28 Formules de dosage de tacrolimus modifiées

Country Status (15)

Country Link
US (1) US20100086592A1 (fr)
EP (1) EP1974722A3 (fr)
JP (1) JP2010522742A (fr)
KR (1) KR20100014629A (fr)
CN (1) CN101652141A (fr)
AU (1) AU2008288105A1 (fr)
BR (1) BRPI0809563A2 (fr)
CA (1) CA2680680A1 (fr)
CL (1) CL2008000914A1 (fr)
EA (1) EA200970897A1 (fr)
IL (1) IL201008A0 (fr)
MX (1) MX2009010556A (fr)
NZ (1) NZ579811A (fr)
UA (1) UA93148C2 (fr)
WO (1) WO2009022354A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167033B1 (fr) * 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Forme pharmaceutique orale à administrer une fois par jour comportant du tacrolimus
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
EP2309999A1 (fr) * 2008-06-26 2011-04-20 McNeil-PPC, Inc. Particules enrobées contenant des agents pharmaceutiquement actifs
KR101174183B1 (ko) 2008-11-28 2012-08-16 주식회사 삼양바이오팜 생체이용률이 향상된 타크로리무스 제제 및 상기 제제의 제조방법
GB2479213B (en) * 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
KR101873075B1 (ko) * 2010-08-18 2018-06-29 에보니크 룀 게엠베하 하나 이상의 알긴산 염을 포함하는 위 내성 제약 또는 건강기능식품 제제
KR101243938B1 (ko) 2010-10-19 2013-03-19 이희엽 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
RU2671575C2 (ru) 2011-05-10 2018-11-02 Теравида, Инк. Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
DE102011053068A1 (de) * 2011-08-29 2013-02-28 Hennig Arzneimittel Gmbh & Co. Kg Darreichungsform mit stabilisierten Wirkstoffpartikeln
KR20130028824A (ko) * 2011-09-09 2013-03-20 주식회사 삼양바이오팜 타크로리무스를 포함하는 고체 분산체 및 이의 제조방법
US10639283B2 (en) * 2012-08-27 2020-05-05 Evonik Operations Gmbh Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
WO2016025533A2 (fr) * 2014-08-11 2016-02-18 Whitehead Institute For Biomedical Research Compositions et méthodes de traitement des synucléinopathies
CN104473907A (zh) * 2014-12-25 2015-04-01 北京华禧联合科技发展有限公司 一种他克莫司的口服缓释制剂
EP3258918A1 (fr) 2015-02-20 2017-12-27 Cytec Industries Inc. Compositions de sulfosuccinate de dialkyle, procédé de fabrication, et méthode d'utilisation
CA3011683C (fr) 2016-01-20 2023-09-26 Theravida, Inc. Methodes et compositions pour le traitement de l'hyperhidrose
JP7520732B2 (ja) 2018-06-29 2024-07-23 インサイト・コーポレイション Ａｘｌ／ｍｅｒ阻害剤の製剤
US20200038560A1 (en) * 2018-07-31 2020-02-06 Cook Medical Technologies Llc Limus coatings and methods of use thereof
CA3063417C (fr) * 2018-12-04 2023-01-03 Leon-Nanodrugs Gmbh Nanoparticules comprenant du tacrolimus
GR1009790B (el) * 2019-03-20 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
CN112569187B (zh) * 2019-09-27 2022-04-12 武汉科福新药有限责任公司 一种他克莫司纳米眼用乳及其制备方法
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064942A1 (fr) * 1998-03-26 2001-01-03 Fujisawa Pharmaceutical Co., Ltd. Preparations a liberation prolongee
WO2005020993A1 (fr) * 2003-08-29 2005-03-10 Lifecycle Pharma A/S Compositions a liberation modifiee, a base de tacrolimus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE531368T1 (de) 2003-08-29 2011-11-15 Veloxis Pharmaceuticals As Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
DE10353196A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
AU2005316473B2 (en) * 2004-12-15 2011-07-14 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064942A1 (fr) * 1998-03-26 2001-01-03 Fujisawa Pharmaceutical Co., Ltd. Preparations a liberation prolongee
WO2005020993A1 (fr) * 2003-08-29 2005-03-10 Lifecycle Pharma A/S Compositions a liberation modifiee, a base de tacrolimus

Also Published As

Publication number Publication date
AU2008288105A1 (en) 2009-02-19
EA200970897A1 (ru) 2010-04-30
BRPI0809563A2 (pt) 2014-09-16
WO2009022354A2 (fr) 2009-02-19
US20100086592A1 (en) 2010-04-08
JP2010522742A (ja) 2010-07-08
EP1974722A2 (fr) 2008-10-01
NZ579811A (en) 2012-02-24
CN101652141A (zh) 2010-02-17
UA93148C2 (ru) 2011-01-10
WO2009022354A3 (fr) 2009-04-09
CA2680680A1 (fr) 2009-02-19
MX2009010556A (es) 2009-10-22
KR20100014629A (ko) 2010-02-10
IL201008A0 (en) 2010-05-17
CL2008000914A1 (es) 2008-07-18

Similar Documents

Publication Publication Date Title
EP1974722A3 (fr) Formules de dosage de tacrolimus modifiées
WO2011118976A3 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une stéatose hépatique non alcoolique et procédé pour la prévention ou le traitement de la stéatose hépatique non alcoolique utilisant celle-ci
WO2011124953A3 (fr) Compositions pharmaceutiques à libération contrôlée de tapentadol
WO2009034541A3 (fr) Formes galéniques à libération contrôlée à base de trimétazidine
IL194871A (en) Compound linking to bir iap site, intermediate compound, process for compound preparation, method for making acceptable pharmaceutical salt, pharmaceutical preparation and use of compound for drug production
ME01394B (fr) Forme cristalline gamma-d du chlorhydrate del'ivabradine, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
EP2508523A3 (fr) Polymorphes de dasatinib et leur procédé de préparation
WO2012021629A3 (fr) Nouveaux agonistes du récepteur dopaminergique d3 pour traiter la dyskinésie dans la maladie de parkinson
WO2006082523A3 (fr) Compositions pharmaceutiques de metformine
TW200745149A (en) Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments
MX2011012122A (es) Derivados de tiofeno.
WO2008062446A3 (fr) Composition de lévétiracétam à libération prolongée n'impliquant pas d'effets indésirables en présence d'aliments
MY160701A (en) Liquid oral composition
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
EA201171271A1 (ru) Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида
WO2012052169A3 (fr) Composition pharmaceutique particulaires contenant un opioïde et un antagoniste d'opioïde
WO2010044097A3 (fr) Nouvelle forme pharmaceutique de palipéridone et procédé de préparation de celle-ci
WO2016091805A3 (fr) Monopréparation de naloxone et comprimé multicouche
MY179041A (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
WO2009115666A3 (fr) Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artémisinine ou l'un de ses derives pour le traitement du paludisme severe
WO2007110765A3 (fr) Procedes de preparation d'octreotide
WO2009043577A3 (fr) 19-norprogestérone utilisée en tant que contraceptif
WO2005023216A3 (fr) Forme galenique multiparticulaire orale formulee par fusion
WO2008005806A3 (fr) Procédés, compositions et composés thérapeutiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

AKX Designation fees paid
17P Request for examination filed

Effective date: 20090825

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121002